Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Study: Eli Lilly Drug To Shift Focus From Pain Control to Disease

By Pharmaceutical Processing | October 25, 2004

WALTHAM, MA (October 25, 2004) – Decision Resources, Inc., a research and advisory firm focusing on pharmaceutical and health care issues, forecasts that Eli Lilly’s launch of ruboxistaurin in 2006 will transform the diabetic neuropathy drug market from a focus on pain control to one of disease modification.

According to the new Decision Resources study entitled “Diabetic Neuropathy,” EliLilly’s ruboxistaurin promises to be the first drug with disease-modifyingpotential that will launch beyond Japan. Epalrestat, available in Japan since1995, is thought to be only moderately effective, according to the research firm.

“Although ruboxistaurin has performed poorly in trials for diabetic retinopathy, interviewed experts remain hopeful that, if this agent is administered early enough in the disease process, it will reduce disease progression of distal symmetrical polyneuropathy, the most common clinical manifestation of neuropathy among diabetics,” according to Carilee Berg, analyst at Decision Resources.

Diabetic neuropathy is a disease in which diabetics’ hyperglycemia leadsto nerve damage. Distal symmetrical polyneuropathy, also known as diabeticperipheral neuropathy, is the most common clinical manifestation of neuropathyamong diabetics. Symptoms include pain and numbness, and the disease can leadto ulcers and even amputation. Distal symmetrical polyneuropathy patients arecurrently treated with drugs to control pain.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE